Selected article for: "activity mechanism and acute respiratory"

Author: Keyaerts, Els; Vijgen, Leen; Maes, Piet; Neyts, Johan; Ranst, Marc Van
Title: Growth kinetics of SARS-coronavirus in Vero E6 cells
  • Cord-id: cqcfstst
  • Document date: 2005_4_15
  • ID: cqcfstst
    Snippet: Vero E6 cells are commonly used for in vitro studies of the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) and for antiviral evaluation purposes. A better understanding of the SARS-CoV growth kinetics in Vero E6 cells is crucial to help elucidate the mechanism of antiviral activity of selective antiviral agents. In this study, the growth kinetics of SARS-CoV in Vero E6 cells were studied by quantitation of intra- and extracellular viral RNA load as well as extracellular viru
    Document: Vero E6 cells are commonly used for in vitro studies of the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) and for antiviral evaluation purposes. A better understanding of the SARS-CoV growth kinetics in Vero E6 cells is crucial to help elucidate the mechanism of antiviral activity of selective antiviral agents. In this study, the growth kinetics of SARS-CoV in Vero E6 cells were studied by quantitation of intra- and extracellular viral RNA load as well as extracellular virus yield at different time points post-infection. At 12 h post-infection, the intracellular viral RNA load was 3 × 10(2)-fold higher than at the time of infection, and the extracellular viral RNA load was increased with a factor of 2 × 10(3). Intracellular viral RNA levels started to rise at 6 h post-infection. One hour later (at 7 h post-infection), the levels of extracellular SARS-CoV RNA also began to rise. This was corroborated by the fact that infectious progeny SARS-CoV also first appeared in the supernatant between 6 and 7 h post-infection. At 12 h post-infection, SARS-CoV reached titers in the supernatant of 5.2 × 10(3) CCID(50)/ml.

    Search related documents:
    Co phrase search for related documents
    • active component and acute sars respiratory syndrome: 1, 2, 3, 4, 5, 6
    • active component and addition drug: 1, 2, 3
    • active component and addition drug time: 1, 2, 3
    • acute sars respiratory syndrome and addition drug: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars respiratory syndrome and addition drug time: 1, 2, 3, 4
    • acute sars respiratory syndrome and addition drug time assay: 1, 2
    • acute sars respiratory syndrome and live virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars respiratory syndrome and live virus presence: 1, 2